CDO1 Promoter Methylation is a Biomarker for Outcome Prediction of Anthracycline Treated, Estrogen Receptor-Positive, Lymph Node-Positive Breast Cancer Patients

Table 2 Time-dependent ROC analysis of the candidate genes in the training and validation set of LNP patients with ER+ tumors treated with adjuvant anthracycline containing therapy.

^†Shown are the AUC of the ROC at 48 months after surgery
^‡ The p-values are those obtained by the log rank test in Kaplan-Meier survival analysis and the genes are ranked according these p-values. The median DNA methylation score from the training set and the validation set, respectively, was used as the cut point.

ISSN: 1471-2407